The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
Allergic diseases represent a major global health burden, placing significant strain on health care systems worldwide. Severe ...
LONDON--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of the final phase I data from the first ever ...
The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows ...
The immunoglobulin E (IgE) antibody is a key mediator of allergic responses in food allergies and allergic rhinitis, commonly known as hay fever. In someone with an allergy, the immune system ...
The mechanism underlying how seasonal allergies recur year after year with precise timing remains largely unknown. An international team led by Professor Rudolf Valenta has identified a specific type ...
Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...
In vitro, omalizumab and human IgE form several immune complexes that vary in size as the 2 components' molar ratios are changed. [29] The largest complex, a stable cyclical hexameric structure ...
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E antibodies in humanized mice, protects against Immunoglobulin E-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results